Nneka is founder and CEO of Pharmaceutical Economics Consultants of America (PEÇΛ). Dr. Onwudiwe’s areas of specialization are public health and health economics. Her work focuses on a variety of projects related to costs and cost-effectiveness, coverage, management, and payment methods for innovative technologies as well as compliance-related issues, including compliance with market-wide requirements of ACA, MHPAEA, and state laws. From 2012-2020, Dr. Onwudiwe was the Patient-reported outcomes (PRO) and Pharmacoeconomics (PE) Regulatory Review Officer at the Food and Drug Administration (FDA).
Dr. Onwudiwe holds a license in pharmacy and practices in the community providing medication therapy management (MTM) and other services.
David P. Miller is the Executive Director of Epidemiology at Sarepta Therapeutics. He is also an Adjunct Faculty member at the University of North Carolina Chapel Hill. In the previous ten years, he was the Global Head of Real World Evidence Methods, Analytics and Safety at UCB Biosciences where his focus has been to evolve a Patient Safety team as a member of the Patient Safety Leadership team, build an Epidemiology team with a focus in delivering scientific relevant evidence, and most recently building a unified Real World Evidence practice with the accountability of setting the evidence standards meeting the current and future quality needs as defined by ISPE and other relevant societies. Prior to UCB, David has worked at GSK and in consulting environment (RTI Health Solutions and Ingenix).
Nneka is founder and CEO of Pharmaceutical Economics Consultants of America (PEÇΛ). Dr. Onwudiwe’s areas of specialization are public health and health economics. Her work focuses on a variety of projects related to costs and cost-effectiveness, coverage, management, and payment methods for innovative technologies as well as compliance-related issues, including compliance with market-wide requirements of ACA, MHPAEA, and state laws. From 2012-2020, Dr. Onwudiwe was the Patient-reported outcomes (PRO) and Pharmacoeconomics (PE) Regulatory Review Officer at the Food and Drug Administration (FDA).
Dr. Onwudiwe holds a license in pharmacy and practices in the community providing medication therapy management (MTM) and other services.
Michelle is currently the Global Medical Information Lead at Idorsia Pharmaceuticals Ltd. She has worked in industry Globally for over 20 years in roles including: Medical Device Sales, Med Info, Pharmacovigilance and Medical Affairs for Ethicon Endo-surgery (a J&J Company), Eli Lilly, Pfizer, Amgen, Shire and Biogen. Michelle is very passionate about Med Info & Med Affairs and is highly motivated by innovative, customer centric ways to support healthcare and non-healthcare professionals around the world to ensure the safe and effective use of medicines.
Global Outcomes Research at Shire, US Evidence Based Medicine at Sanofi, and Global Health Outcomes at Merck & Co. Tao led numerous real world data strategy, health technology assessment and research in real world evidence, HEOR & analytics across many countries worldwide, and authored numerous peer reviewed scientific articles, book chapters and abstracts at national and international scientific meetings.
Dr. Covington is an executive leader at Curio Digital Therapeutics, Inc where she serves as Senior Vice President, Research and Patient Outcomes. Prior to this, she was VP of RWD at Ciox Health, a technology company. She is focused on developing patient-centered approaches for clinical and real-world evidence to inform health outcomes and disease prevention. Melva’s background is in public health outcomes research (HEOR) and strategic thinking. She has deep analytic RWE and market access experience gained across Pharma, therapeutic areas and product lifecycles.
Melva has been a leader across multiple business functions, which include medical affairs, business development, clinical operations, health advocacy and field-based engagement. She is focused on developing, supporting and mentoring emerging leaders for global impact.
Melva has led Global and US-based teams for Roche Labs, Eli Lilly, Sanofi, Pacira and Eversana. She is passionate about integrating data and consumer perceptions into knowledge documents and solutions that improve outcomes across diverse patient populations.
She has an A.B. in Politics/Economics from The Catholic University of America, MPH and Ph.D. from the University of North Carolina at Chapel Hill. She also holds a MBA from the Johnson School at Cornell University, has authored numerous publications, is patient advocate and impassioned public speaker.
Joel is currently responsible for the development of the value proposition of RNA therapies for Duchenne Muscular Dystrophies at Sarepta Therapeutics in Cambridge MA. His role includes generating HEOR evidence and market access strategies to support global access of the company’s RNA products. Prior to joining Sarepta Therapeutics, Joel was team leader and project manager at Mapi ICON. Joel also held various positions with increasing responsibilities at Johnson & Johnson in Switzerland where he developed, led and executed health economics and market access strategies. Joel started his career in the market access team at Sanofi Switzerland, where he contributed to HTA submissions to the Swiss health authorities.
Joel holds a PharmD, a PhD degree in Pharmaceutical Sciences and an MBA, both from the University of Geneva, Switzerland. He also holds a diploma in Health Economics from the University of York, UK.
An Account Executive with over 25 years of experience spearheading and implementing clients’ solution needs in the Life Sciences Industry towards Dedalus' mission of digitizing the Life Sciences value chain of pioneering next generation solutions harnessing real world data, automation and advanced analytics. A progressive career within diverse business spheres including global service delivery, account development, project management, product development and architecture. Additional responsibilities include customer satisfaction, management of Life Sciences partnerships, projects and programs, relationship management and business development. In his previous role, Sharad was the Portfolio Director for DXC Life Sciences where he was responsible for the strategy and portfolio of the products and solutions. Sharad has a Bachelor of Computer Science degree from the University of Witwatersrand, South Africa and an MBA from Suffolk University in the United States. Sharad resides in New Jersey and is well connected with strong industry relationships.
In this role, he leads oncology team for the development and execution of integrated value strategy plan and evidence generation for launched and pipeline oncology assets.
Frank has over a decade of diverse HEOR experience in different therapeutic areas including oncology, nephrology, and nutrition. He started his career with Baxter Healthcare International in 2009, where he advanced his career from Manager to Director HEOR. Between 2015 and 2019, he was Director, Outcomes Research, with Merck & Co., Inc. (MSD outside North America) in its Center for Observational and Real-World Evidence.
Frank received his PhD in Pharmacoeconomics and Outcomes Research from the University of Illinois at Chicago. He has authored/coauthored 50+ peer-reviewed journal publications and 90+ abstracts/presentations at national/international congresses.
Dr. Richard Gliklich, MD is the CEO of OM1, Inc. Previously, he was founder and CEO of Outcome, which he led from inception through its acquisition by Quintiles. Dr. Gliklich is well known in the areas of registries, outcomes and analytics. He is senior editor of the landmark publication by the U.S. Agency for Healthcare Research and Quality (AHRQ) handbook "Registries for Evaluating Patient Outcomes: A User's Guide” and the PI for the Outcomes Measures Framework, which focuses on standardization of outcomes measurement. He has led several key national and international efforts focused on evaluating the safety, effectiveness, value and quality of healthcare. Dr. Gliklich also holds several patents for both health outcomes systems and medical devices. Dr. Gliklich is a graduate of Yale University and Harvard Medical School and a former Charles A. Dana Scholar at the University of Pennsylvania. He is also a surgeon and the Leffenfeld Professor at Harvard Medical School.
David P. Miller is the Executive Director of Epidemiology at Sarepta Therapeutics. He is also an Adjunct Faculty member at the University of North Carolina Chapel Hill. In the previous ten years, he was the Global Head of Real World Evidence Methods, Analytics and Safety at UCB Biosciences where his focus has been to evolve a Patient Safety team as a member of the Patient Safety Leadership team, build an Epidemiology team with a focus in delivering scientific relevant evidence, and most recently building a unified Real World Evidence practice with the accountability of setting the evidence standards meeting the current and future quality needs as defined by ISPE and other relevant societies. Prior to UCB, David has worked at GSK and in consulting environment (RTI Health Solutions and Ingenix).
Andrew Larsen is the Director of Life Sciences Partnership at PicnicHealth, where he works with biopharma, health tech, and advocacy to achieve their real-world evidence goals. Prior to transitioning to PicnicHealth, he was an engagement manager at ClearView, a life sciences strategy consulting firm, where he oversaw a range of projects involving therapeutic area, disease, and asset level growth strategy. Andrew completed his postdoctoral fellowship and doctoral training at the Johns Hopkins University School of Medicine, focusing on oncology. He was awarded his Ph.D. in Cellular and Molecular Medicine.
Will Herring, PhD, is a Senior Director in the Health Economics group at RTI-HS and provides a strong interest and extensive background in mathematical modeling and decision analysis across the healthcare system. Over more than a decade with RTI-HS, Dr. Herring has developed an expertise in cost-effectiveness and value-based pricing modeling, and his models have been used to inform strategic decisions during the development of new health technologies and to support submissions to healthcare payers and regulatory agencies. Most recently, his research has focused on economic modeling for chronic progressive diseases (Alzheimer’s disease [AD], multiple sclerosis, and nonalcoholic steatohepatitis) and for conditions and interventions affecting elderly populations (AD, herpes zoster vaccination, and respiratory syncytial virus vaccination). Dr. Herring has presented his research on economic modeling and value assessment challenges for AD in multiple national and international settings and is a member of the steering committee for the International Pharmaco-Economic Collaboration for Alzheimer’s Disease (IPECAD) Modelling Group. His therapeutic area experience extends to a range of other therapeutic areas, including ophthalmology (diabetic retinopathy and age-related macular degeneration), respiratory (asthma and chronic obstructive pulmonary disease), dermatology (atopic dermatitis and psoriasis), diabetes, chronic hepatitis C, and oncology. Dr. Herring is a member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and the ISPOR Open-Source Modeling Special Interest Group and has presented his work at professional conferences and workshops. His research has been published in peer-reviewed journals, including PharmacoEconomics, Journal of Managed Care and Specialty Pharmacy, and Neurology and Therapy.
Dr. Prasun Mishra is an investor, co-founder, advisor, and board member of a few US-based corporations; he has numerous publications/patents, several drugs in clinical trials, and has over 40 prestigious awards honors to his credit. He is the founder and CEO of Agility Pharmaceuticals, a technology-driven pharmaceutical company committed to revolutionizing drug discovery & development. Dr. Mishra is also the founding president and chair of the American Association for Precision Medicine and the AAPM Innovation Center, where he is leading research efforts focused on preventing & curing chronic diseases, treating the sick, and providing knowledge/tools to individuals to live longer, healthier lives.
He is a serial entrepreneur who founded his first company after graduating high school and his second company during his Ph.D. Since then, he has accumulated a wealth of experience by building, investing, and advising numerous other companies. He is also a General Partner in the Global Health Impact Network and Fund, a healthcare-focused investment fund based in Silicon Valley, CA. He is also a founding chair of WISE: World Investors and Entrepreneurs Society, an investment collective with a global investment footprint. He is a founding investor and advisor to Barcelona Ventures and an advisor to a $100M private equity fund.
He served as a Scientist and Principal Investigator at the pharma giant Genentech, Roche. Where he participated in several drug discovery project teams; moreover, his passion for drug development and precision medicine has led to the identification of new drug targets, biomarkers, companion diagnostics, and several drugs/ combinations in the clinic.
As founder and CEO of LynxCare, Georges De Feu is committed to increase the availability of actionable & precise data with the sole goal of improving patient outcomes
Usha Periyanayagam, MD, MPH is a physician working at the intersection of data and medicine. She is currently the Head of RWE and Clinical Product at Komodo Health. In this role, she uses her clinical knowledge to translate data into actionable insights for life sciences companies, advocacy organizations, payers, and providers. She is also board certified in emergency medicine and continues to practice at Kaiser Hospital.
Previously, Dr. Periyanayagam was the medical lead at Agathos, where she explored EMR and claims data to highlight variation in clinical care. She was also an Instructor of Emergency Medicine at Harvard University, and she has extensive global health experience, including medical practice and epidemiological research in Uganda, South Sudan and Pakistan. Dr. Periyanayagam has been recognized by MedTech Boston’s list of “40 under 40 Healthcare Innovators” and by LinkedIn’s “Next Wave” in healthcare. She earned her MD, MPH in biostatistics, and BS in biomedical engineering from Northwestern University.
Jennifer is Vice President, Science at Aetion. Dr. Polinski is an epidemiologist and pharmacoepidemiologist with more than 20 years of experience in the healthcare industry and academia. Before joining Aetion, Dr. Polinski held analytics leadership roles at CVS Health and at Haven, the Amazon, Berkshire Hathaway, JPMorgan Chase healthcare venture. In both roles, she led teams in the use of big data to assess the impact of health care interventions and drugs on patient experience, clinical outcomes and patient and payer costs. Prior to her industry experience, she was an Assistant Professor at Harvard Medical School and the Harvard T.H. Chan School of Public Health, during which time she received the Bernie J. O’Brien New Investigator Award from ISPOR. She has published more than 70 articles in peer-reviewed medical journals. Dr. Polinski received her bachelor’s degree from the University of Virginia, master’s degrees from both Emory University (Public Health) and Harvard T.H. Chan School of Public Health (Epidemiology), and a doctorate degree in epidemiology from the Harvard T.H. Chan School of Public Health.
Tabby Khan, MD, MPH, is a Lead Clinical Product Specialist at Komodo Health. She provides clinical inputs into all of Komodo’s products and overseeing patient cohort development and analysis. Tabby has over ten years of experience in healthcare and has previously worked as a clinical research coordinator, research fellow, and clinician.
Before Komodo Health, Tabby was a clinical research fellow and general surgery resident at the University of Florida. She completed several clinical research projects within the Division of Vascular Surgery in the Department of Surgery and has presented her work at national meetings and has been published in top journals such as Annals of Surgery and Journal of Thoracic Surgery.
Tabby graduated with a bachelor’s degree in neuroscience and behavior from Columbia University and an MD/MPH dual degree from Emory University, where her thesis work focused on racial disparities in lung transplantation
